Hour24 News

Sophisticated and simple

NEWS

/

Clinical oncology / targeted therapy

Jan 10, 2026

Clinical oncology / targeted therapy /

Continued Zenocutuzumab Beyond Progression Benefits NRG1+ Pancreatic Cancer and Cholangiocarcinoma, ASCO GI Presents New eNRGy Trial Data

New insights from ASCO GI: Zenocutuzumab beyond progression in NRG1+ cancers At ASCO GI, researchers presented post hoc analyses from the eNRGy trial (NCT02912949) highlighting…